Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (163)

« Back to Publications

Structure-Guided Design of ISOX-DUAL-Based Degraders Targeting BRD4 and CBP/EP300: A Case of Degrader Collapse.

Edmonds AK. et al, (2025), J Med Chem, 68, 9638 - 9660

Inhibition of MLLT1 limits growth of MLL-AF4 leukaemias without killing healthy haematopoietic stem cells

Rajhansa S. et al, (2025)

Binding-Site Purification of Actives (B-SPA) Enables Efficient Large-Scale Progression of Fragment Hits by Combining Multi-Step Array Synthesis With HT Crystallography.

Grosjean H. et al, (2025), Angew Chem Int Ed Engl, 64

Covalent Inhibitors of S100A4 Block the Formation of a Pro-Metastasis Non-Muscle Myosin 2A Complex.

Giroud C. et al, (2024), J Med Chem, 67, 18943 - 18956

Engineered HMGB1 construct with tandem HMG B domains promotes tissue regeneration without potential for deleterious inflammation or thrombosis

Viñals Guitart Á. et al, (2024)

Unexpected Noncovalent Off-Target Activity of Clinical BTK Inhibitors Leads to Discovery of a Dual NUDT5/14 Antagonist.

Balıkçı E. et al, (2024), J Med Chem, 67, 7245 - 7259

Discovery of a Potent, Selective, and Cell-Active SPIN1 Inhibitor.

Xiong Y. et al, (2024), J Med Chem, 67, 5837 - 5853

Imidazo[1,2-b]pyridazines as inhibitors of DYRK kinases.

Henderson SH. et al, (2024), Eur J Med Chem, 269

Discovery of PFI-6, a small-molecule chemical probe for the YEATS domain of MLLT1 and MLLT3.

Raux B. et al, (2024), Bioorg Med Chem Lett, 98

Enabling equitable and affordable access to novel therapeutics for pandemic preparedness and response via creative intellectual property agreements.

Griffen EJ. et al, (2024), Wellcome Open Res, 9

Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors.

Boby ML. et al, (2023), Science, 382

Turning high-throughput structural biology into predictive inhibitor design.

Saar KL. et al, (2023), Proc Natl Acad Sci U S A, 120

Discovery and Development Strategies for SARS-CoV-2 NSP3 Macrodomain Inhibitors.

Schuller M. et al, (2023), Pathogens, 12

Discovery of High-Affinity Small-Molecule Binders of the Epigenetic Reader YEATS4.

Londregan AT. et al, (2023), J Med Chem, 66, 460 - 472

Novel Inhibitors of MLLT1/3, a Critical Component of the Super-Elongation Complex (SEC), Target a Range of Molecularly Defined Acute Leukemias, with a Differential Profile to Menin Inhibition

Pollard J. et al, (2023), BLOOD, 142

Load More

1
2
3
4
5
6
7
...
»